Fate Therapeutics, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Bahram Valamehr M.B.A., Ph.D.
- Full Time Employees
- 181
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12278 Scripps Summit Drive San Diego CA United States of America 92131
- IPO Date
- Oct 1, 2013
- CIK
- 0001434316
- Website
- fatetherapeutics.com
- Similar Companies
- Business
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Company News
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Announces Leadership Transition
Fate Therapeutics to Present at Upcoming December Investor Conferences
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates